

Electronic Supporting Information for Publication

Intermolecular benzoyl group transfer reactivity in crystals of racemic 2,6-di-*O*-benzoyl-*myo*-inositol 1,3,5-orthobenzoate: Controlling reactivity by solvate (pseudopolymorph) formation

Shobhana Krishnaswamy,^{a,b} Mysore S. Shashidhar^{b} and Mohan M. Bhadbhade^{c*}*

^a Center for Materials Characterization, National Chemical Laboratory (Council of Scientific and Industrial Research), Pashan Road, Pune 411008, India

Fax: 91-20-25902642; Tel: 91-20-25902252; E-mail: s.krishnaswamy@ncl.res.in

^b Division of Organic Chemistry, National Chemical Laboratory (Council of Scientific and Industrial Research), Pashan Road, Pune 411008, India


Fax: 91-20-25902629; Tel: 91-20-25902055; E-mail: ms.shashidhar@ncl.res.in

^c Mark Wainwright Analytical Center, University of New South Wales, Sydney, Australia.

Fax: 61-2-93854663; Tel: 61-2-93859898; E-mail: m.bhadbhade@unsw.edu.au

Table of Contents

Fig. S1 Proton nmr spectrum for Form II crystals of rac-3	S2
Fig. S2 Proton nmr spectrum for Form III crystals of rac-3	S3
Fig. S3 DSC curve for Form III crystals of rac-3	S4
Fig. S4 Hot stage microscopy images for Form II crystals of rac-3	S4
Table S1 Crystallographic data table for Form II crystals of rac-3	S5
Fig. S5 ORTEP of molecules in Form II crystal of rac-3	S6
Fig. S6 Molecular overlap of Form I and Form II crystals of rac-3	S7
Table S2 Hydrogen bonding interactions in the Form II crystals of rac-3	S7
Fig. S7 Figure showing El-Nu parameters for Form II crystals of rac-3	S8
Fig. S8 Simulated & recorded PXRD patterns for crystalline forms of rac-3	S9






Fig. S2 Proton NMR spectrum of Form III crystals of **rac-3**. Inset shows the solvent (toluene) peaks.




Fig. S3 DSC curve for Form III crystals of **rac-3**.




Fig. S4 Hot stage microscopy images for Form II crystals of **rac-3**.

Table 1 Crystal data table for Form II crystals of **rac-3**.

	rac-3 - Form II
Chemical formula	C ₂₇ H ₂₂ O ₈ · [0.25(C ₃ O); 0.125 (C ₃ O) · 0.25 (O); 0.125 (O)]
M _r	489.22
Crystal size	0.10×0.01×0.01
Crystal system	Triclinic
Space group	<i>P</i> -1
<i>a</i> (Å)	6.1780(12)
<i>b</i> (Å)	15.941(3)
<i>c</i> (Å)	28.069(6)
α (°)	84.21(3)
β (°)	87.52(3)
γ (°)	85.76(3)
V (Å ³)	2740.9(9)
Z, <i>D</i> _{calc} (g cm ⁻³)	4, 1.186
μ (mm ⁻¹), <i>F</i> (000)	0.088, 1025
<i>T</i> _{min} , <i>T</i> _{max}	0.9913, 0.9991
<i>h</i> , <i>k</i> , <i>l</i> (min, max)	(-6,6), (-18,18), (-32,33)
Reflns collected	10041
Unique reflns	6869
Observed reflns	2306
No. of parameters	673
GoF	0.922
R ₁ [<i>I</i> > 2σ(<i>I</i>)]	0.2157
wR ₂ [<i>I</i> > 2σ(<i>I</i>)]	0.4424
R ₁ _all data	0.2992
wR ₂ _all data	0.5000
Δρ _{max} ,Δρ _{min} (eÅ ⁻³)	0.47, -0.42
CCDC dep. No.	787939




Fig. S5 Representative ORTEP for molecules in Form II crystals of **rac-3**. Thermal ellipsoids are drawn at 50% probability and hydrogen atoms are shown as small spheres of arbitrary radii.





Fig. S6 Molecular overlap of Form I and Form II crystals showing the conformational differences.

Table S2 Hydrogen bonding interactions in Form II crystals forming chain along the *a*-axis

D-H…A	D-H /Å	H…A /Å	D…A /Å	D-H…A /°
O6B-H6OB…H4A ⁱ	0.82	2.12	2.934(12)	170
C4A-H4A…O3B ⁱⁱ	0.98	2.51	3.417(14)	153
C4B-H4B…O3A ⁱ	0.98	2.54	3.422(16)	149
C2A-H2A…O6A ⁱⁱⁱ	0.98	2.33	3.203(15)	148
C2B-H2B…O6B ⁱⁱⁱ	0.98	2.37	3.233(16)	146
C5B-H5B…O1B ⁱⁱ	0.98	2.57	3.450(16)	150

Symmetry codes: (i) x, y, z ; (ii) $1+x, y, z$; (iii) $-1+x, y, z$.



$\text{O}=\text{C}\dots\text{O-H}$	$d(\text{C}\dots\text{O}) / \text{\AA}$	$\angle(\text{O}=\text{C}\dots\text{O}) / {}^\circ$
$\text{O4B}=\text{C8B}\dots\text{O6A}$	3.891	34.93
$\text{O4A}=\text{C8A}\dots\text{O6B}$	3.947	30.24

Fig. S7 Closely interacting molecules in the chain along *a*-axis with the El-Nu parameters which are not conducive for acyl transfer reaction in the solid-state.




Fig. S8 Simulated (Form I, Form II) and recorded (Form III) PXRD patterns of crystals of **rac-3**.